ArticlePharmacogenomics and personalized medicine2023

Resistance to PARP Inhibitors After First-Line Platinum-Based Chemotherapy in a Patient with Advanced Ovarian Cancer with a Pathogenic Somatic BRCA1 Mutation.

Lan Zhong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.